MetaCap

Nuvectis Pharma Inc. (NVCT)

NASDAQ: NVCTHealth CareBiotechnology: Pharmaceutical PreparationsUSD

19.39-0.45 (-2.27%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NVCT stock chart

Technical analysis

Key statistics

All statistics
Market cap
$666.80M
EPS (TTM)
-$2.00
52-week range
5.77 – 29.28
Day range
19.02 – 20.18
Volume / Avg
301.60K / 206.37K
Beta
—

52-week range

$5.77$29.28

NVCT stock today

On Nov 20, NVCT ended the session at $19.39, shedding $0.45 (2.27%), versus the S&P 500's 3.70% decline. Shares are 33.8% below their 52-week high of $29.28, set on Jun 29, 2026 and 236.0% above the 52-week low of $5.77, in the middle of the past year's range. NVCT is up 156.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 218.9%.

Nuvectis Pharma has posted a net loss over the last twelve months (EPS of -$2.00), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Nuvectis Pharma

Company profile

Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Ron Bentsur M.B.A.
Headquarters
Fort Lee, NJ
Employees
19
IPO year
2022

Financial highlights

Full financials

Nuvectis Pharma reported a net loss of $26.4 million, compared with a loss of $19.0 million a year earlier. Diluted earnings per share came in at -$1.32.

Nuvectis Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-26.44M$-19.00M$-22.26M$-19.09M$-12.89M
EPS (diluted)$-1.32$-1.11$-1.43$-1.51$-3.02

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$35.40+82.57%

  • Strong buy 2
  • Buy 4
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $30.00High $40.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.44 vs $-0.22
Surprise
-100.00%

NVCT news

All NVCT news

Nuvectis Pharma peers

Health Care sector
NVCT peer companies
CompanyPrice% ChgMarket capCompare
APMDApnimed Inc.16.09-6.70%$669.84Mvs NVCT
LXRXLexicon Pharmaceuticals Inc.1.53-8.38%$681.21Mvs NVCT
SGMTSagimet Biosciences Inc. Series A9.08-5.61%$648.02Mvs NVCT
KURAKura Oncology Inc.6.91-5.99%$634.88Mvs NVCT
JANXJanux Therapeutics Inc.10.08-2.04%$616.73Mvs NVCT
ABUSArbutus Biopharma Corporation4.02-1.23%$616.24Mvs NVCT
OLMAOlema Oncology Inc.7.02-1.82%$615.00Mvs NVCT
OBXObsidian Therapeutics Inc.12.00-1.23%$741.29Mvs NVCT

Indexes, lists and sector

Nuvectis Pharma stock FAQ

What is Nuvectis Pharma's stock price today?

NVCT last traded at $19.39 as of Nov 20, 4:00 PM EST, down 2.27% on the day. Prices are delayed at least 15 minutes.

Who is Nuvectis Pharma's CEO?

Mr. Ron Bentsur M.B.A. is the chief executive officer of Nuvectis Pharma Inc., which has about 19 employees.

What is the NVCT 52-week high?

The 52-week high for NVCT is $29.28 and the 52-week low is $5.77. The stock is currently 33.8% below its high.

Compare NVCT